Magrey Marina, Bozyczko Michael, Wolin Daniel, Mordin Margaret, McLeod Lori, Davenport Eric, Chirila Costel, Park Yujin
Division of Rheumatology, The MetroHealth System and School of Medicine, Case Western Reserve University, 2500 MetroHealth Dr., Cleveland, OH, 44109, USA.
National Psoriasis Foundation, Portland, OR, USA.
Drugs Real World Outcomes. 2019 Jun;6(2):83-91. doi: 10.1007/s40801-019-0154-4.
This real-world study evaluated the feasibility of assessing patient-reported symptom improvement and treatment satisfaction using a web-based survey among patients with ankylosing spondylitis (AS) treated with secukinumab.
This cross-sectional, web-based survey collected data on demographics, symptoms, treatment history, and treatment satisfaction from US patients with AS who were receiving secukinumab at survey participation. Patients reported AS symptoms experienced before and after secukinumab initiation, time to symptom improvement, and satisfaction with secukinumab treatment.
Of 2755 patients screened, 200 with AS were included in the analysis. The mean (SD) age of patients was 34.4 (10.6) years; 86.5% were biologic experienced. Most (74.0%) reported overall improvement ("a little," "moderately," or "much better") in AS symptoms since secukinumab initiation compared with before secukinumab initiation; a similar trend was observed for all the individual symptoms analyzed (pain disrupting sleep, fatigue, morning stiffness, pain and stiffness in lower back or neck, sore areas other than joints, and ankle or heel pain [indicating enthesitis]). Approximately 41.9% of patients reported overall symptom improvement within 4 weeks of secukinumab treatment. Most expressed overall satisfaction ("very," "mostly," or "somewhat satisfied") with secukinumab regarding symptom improvement (99.0%), speed of symptom improvement (97.0%), frequency and method of administration (96.0% and 91.5%, respectively), ease of use (93.5%), patient support services (97.0%), and side effects, if any (93.0%).
Most patients reported overall symptom improvement and satisfaction with treatment. Our study indicates that patient-reported perspectives may be feasibly collected using a web-based survey to provide insights into treatment experience and satisfaction.
这项真实世界研究评估了在接受司库奇尤单抗治疗的强直性脊柱炎（AS）患者中，使用基于网络的调查来评估患者报告的症状改善情况和治疗满意度的可行性。
这项横断面、基于网络的调查收集了参与调查时正在接受司库奇尤单抗治疗的美国AS患者的人口统计学数据、症状、治疗史和治疗满意度。患者报告了司库奇尤单抗开始使用前后经历的AS症状、症状改善时间以及对司库奇尤单抗治疗的满意度。
在2755名筛查的患者中，200名AS患者纳入分析。患者的平均（标准差）年龄为34.4（10.6）岁；86.5%有生物制剂使用经验。大多数（74.0%）报告自司库奇尤单抗开始使用以来，与用药前相比，AS症状有总体改善（“略有改善”“中度改善”或“明显改善”）；在所分析的所有个体症状（干扰睡眠的疼痛、疲劳、晨僵、下背部或颈部疼痛和僵硬、关节以外的疼痛部位以及踝关节或足跟疼痛[提示附着点炎]）中均观察到类似趋势。约41.9%的患者在司库奇尤单抗治疗4周内报告总体症状改善。大多数患者对司库奇尤单抗在症状改善（99.0%）、症状改善速度（97.0%）、给药频率和方式（分别为96.0%和91.5%）、易用性（93.5%）、患者支持服务（97.0%）以及副作用（如有，93.0%）方面总体满意（“非常满意”“大多满意”或“有些满意”）。
大多数患者报告总体症状改善和对治疗满意。我们的研究表明，使用基于网络的调查可以切实收集患者报告的观点，以深入了解治疗体验和满意度。
